Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,543 questions · 2,589 findings · 168 reviews · Schizophrenia

No studies found 601 · 23.2%GRADE not reported 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%

HALOPERIDOL vs first‐generation antipsychotics

Clinically important response to treatment (short term) · patients with schizophrenia

Haloperidol showed no clear difference in clinically important response to treatment (short term) compared with first‐generation antipsychotics (low certainty).

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Adverse events as N of participants with at least one adverse event objective · patients with schizophrenia

It is very uncertain whether haloperidol changes adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (medium term) · patients with schizophrenia

It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia

It is very uncertain whether haloperidol changes leaving the study early due to adverse events as a measure of… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Number of participants reporting an adverse event · patients with schizophrenia

Haloperidol showed no clear difference in adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (low certainty).

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Response to treatment (medium term) Clinically important response to treatment as defined by each study · patients with schizophrenia

Haloperidol may leads to lower clinically important response to treatment (medium term) compared with first‐generation antipsychotics (low certainty).

1 finding from 1 review

HALOPERIDOL vs first‐generation antipsychotics

Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia

It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).

1 finding from 1 review

Pyridoxal 5 phosphate (vitamin B6) vs placebo

Clinical efficacy ‐ improvement (> 40%) in ESRS scores from baseline ESRS1 · patients with antipsychotic‐induced tardive dyskinesia

Pyridoxal 5 phosphate (vitamin B6) may leads to higher clinical efficacy ‐ improvement (> 40%) in ESRS scores from baseline… compared with placebo (low certainty).

1 finding from 1 review